DailyIQ
Last updatedUpdating…

TECH·Bio-Techne Corporation

$72.53
+0.05 (+0.07%)
High
$72.54
Open
$72.50
Market Cap
11.37B
52W High
$74.00
Low
$72.48
P. Close
$72.53
P/E
62.55
52W Low
$43.00
Fwd P/E
31.34
DailyIQ Est.
$70.73
Inst. Ownership
61.8%
Short Interest
4.71%
Days to Cover
2.1
Div. Yield
0.44%
Next Ex-Div
~Nov 24
Technical Score (1D)
67
BULLISH
News Sentiment
34
BEARISH
TECH is registering a BUY signal on the 1D chart with a score of 67 and firm momentum. The price structure is bullish and constructive, which means the chart is doing what it should. The friction is sentiment: at 34, it's diverging from the technical direction, and that gap between the chart and the news backdrop is worth keeping in mind. Setups with this kind of split can still deliver clean continuation moves - especially when price is near support and momentum is intact - but they tend to need a technical catalyst rather than purely riding news tailwinds. Watch for a push above $75.43 as the sign that buyers are willing to absorb the lukewarm sentiment backdrop. A loss of $69.63 would suggest the sentiment divergence is starting to win. The gap between the 1D chart and the sentiment read is the kind of thing that shows up in hindsight as either the setup that shook out weak hands before running, or the one that should have been faded. Until $75.43 clears with real volume, sizing should reflect that ambiguity rather than the technical score in isolation - $69.63 is the level where that ambiguity gets resolved one way or the other.
LOW TARGET
$50 -31.1%
3 analysts
MEAN TARGET
$71 -2.8%
13 analysts
HIGH TARGET
$73 +0.7%
8 analysts
PRICE RANGE
$50.00 - $73.00
SB / B / H / S / SS
3/4/15/1/1
DAILYIQ EST.
$70.73 (-2.5%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United States
Symbol
TECH
Description
Bio-Techne Corporation is a global provider of life science reagents, instruments, and services, serving the research, diagnostics, and bioprocessing sectors. The company's core business is split into two segments: Protein Sciences, which offers a diverse portfolio of biological reagents and analytical tools for protein analysis, and Diagnostics and Spatial Biology, which focuses on developing diagnostic products and assays. Bio-Techne's Protein Sciences segment provides critical tools for cell and gene therapy, while its Diagnostics segment develops products for regulated diagnostics and advanced tissue analysis. The company's offerings support a variety of applications, from basic research to clinical diagnostics, positioning Bio-Techne as a key supplier in the expanding life sciences market. Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne has evolved to meet the evolving needs of the scientific community.
Bought (1Y)
0 shares
$0
Sold (1Y)
94,894 shares
$6.8M
HIGGINS JOHN L-
Option Exercise15,940 shares2026-09-28
HIGGINS JOHN L-
Tax Withholding5,562 shares2026-09-28
HIGGINS JOHN L-
Option Exercise15,940 shares2026-09-28
BAUMGARTNER ROBERT V-
Option Exercise15,940 shares2026-09-22
BAUMGARTNER ROBERT V-
Tax Withholding5,559 shares2026-09-22
73/ 100
Bullish
Overall: Bullish
✕Revenue declining year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
65.8%
Net Margin
15.0%
Revenue CAGR
9.4%
Current Ratio
4.55x
Debt / Equity
0.10x
Return on Equity
8.6%
Earnings Summary
Bio‑Techne Corporation, a Minneapolis‑based life‑science supplier, delivers reagents, instruments, and services across protein sciences and diagnostics, positioning it within the expanding biotechnology sector. In the most recent quarters, Q4 2024 and Q1 2025, the company posted EPS of $0.42 and $0.56, respectively, both beating estimates of $0.38973 and $0.50718, while revenue rose from $297.0 M to $316.2 M, reflecting a 6.4% increase. The following quarter, Q2 2025, saw EPS of $0.53 versus an estimate of $0.50097 and revenue of $316.96 M, a modest 0.3% uptick, but Q3 2025 reversed momentum with EPS of $0.42 against an estimate of $0.4215 and revenue falling to $286.6 M, a 9.5% decline. Historically, the firm has maintained a steady YoY revenue growth trajectory, with consistent EPS beats in the first three quarters of 2025, yet the Q3 dip indicates a potential slowdown. The company’s recent news highlights a shareholder‑approved Merck KGaA takeover offer and the opening of a flagship Customer Experience Center in Düsseldorf, Germany, which may enhance European market penetration and customer engagement; however, no immediate earnings impact has been reported.

EPS

EstBeatMiss
$0.40$0.44$0.49$0.54$0.58Q1'25Q2'25Q3'25Q2'26Q3'26Q1'27
QtrEstActual+/−
Q1'27$0.45 - -
Q3'26$0.53$0.53-0.8%
Q2'26$0.54$0.46-14.5%
Q3'25$0.42$0.42-0.4%
Q2'25$0.50$0.53+5.8%
Q1'25$0.51$0.56+10.4%

Revenue

EstBeatMiss
$282M$292M$302M$312M$322MQ1'25Q2'25Q3'25Q2'26Q3'26Q1'27
QtrEstActual+/−
Q1'27$298M - -
Q3'26$316M$311M-1.5%
Q2'26$317M$296M-6.5%
Q3'25 - $287M -
Q2'25 - $317M -
Q1'25 - $316M -

Market Data

TECH Stock Snapshot

BULLISH67/100
$72.53+$0.05 (0.1%)
Market cap
11.37B
P/E ratio
62.5
Day range
$72.48 – $72.54
News sentiment
34/100 · Bearish
Analyst target
$70.50 (-2.8%)
Consensus
Hold · 24 analysts
52-week range+68.7% off low · -2.0% from high
$43.00$74.00
Price $72.53 DailyIQ Est. $70.73

Momentum is working in TECH's favour - it ranks in the upper part of DailyIQ's momentum universe. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into TECH?

RICH

At today's price, Bio-Techne Corporation needs to grow free cash flow about 32.8% a year for the next 10 years to justify its valuation at a 10.21% cost of capital. Over its actual history it has compounded free cash flow at 6.5% a year, so the market is asking for 26.2 percentage points above its own delivered rate. On that basis TECH looks priced above what its own growth record supports.

Implied FCF growth
32.8%
Historical FCF CAGR
6.5%
Growth gap
+26.2 pts
Verdict
RICH
Discount rate (WACC)
10.21%
Beta
1.02

Behaviour On Record

What TECH's own history says about today's numbers

Realized volatility (21d)
2.1% 0th pct
Below its peak
-46.2%
vs 200-day average
+16.0%
Up days (1y)
51%

Bio-Techne Corporation is currently running 2.1% annualised volatility over the last 21 sessions. Measured against TECH's own 13 years of daily returns rather than a market-wide average, that is the 0th percentile — unusually subdued by its own history, against a typical reading of 26.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

TECH is trading -46.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -43.1% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +16.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 81st percentile — a wider gap than this stock usually carries. Over the past year TECH closed higher on 51% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, TECH finished the month higher 7 of 13 times, with a median return of +1.1% and an average of -1.1%. Its strongest month historically has been July at +4.7% on average, its weakest August at -3.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: TECH has opened more than 2% away from the prior close in 148 of 3,267 sessions (4.5% of the time), with the largest gaps running +9.7% and -16.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against TECH's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of TECH's sector?

Bio-Techne Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, TECH ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#9 of 15

Options Market

What is the options market pricing for TECH?

CallsPuts

For Bio-Techne Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.01), with at-the-money implied volatility around 24.8%. The options market is pricing roughly a ±5.4% move by that expiry — a range of about $68.63–$76.43.

Put/call ratio (2026-10-16)
0.01
ATM implied volatility
24.8%
Total open interest
18,491
Expected move by 2026-10-16
±5.4% ($68.63–$76.43)

Analyst Rating Changes

Are analysts turning bullish or bearish on TECH?

Wells Fargo most recently downgraded Bio-Techne Corporation to Equal-Weight on Aug 13, 2026 with a price target of $73 (from $62). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Wells Fargo — Equal-Weight
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Aug 13, 2026Wells FargoDowngradeOverweight → Equal-Weight$62 → $73
Jul 9, 2026RBC CapitalDowngradeOutperform → Sector Perform$62 → $73
Jun 30, 2026TD CowenDowngradeBuy → Hold$65 → $73
Jun 30, 2026BenchmarkDowngradeBuy → Hold-
Jun 29, 2026CitigroupDowngradeBuy → Neutral$70 → $73
Jun 26, 2026Stephens & Co.DowngradeOverweight → Equal-Weight$68 → $73
Jun 26, 2026William BlairDowngradeOutperform → Market Perform-
Jun 26, 2026BairdMaintainedNeutral$49 → $73
Jun 11, 2026Piper SandlerInitiatedNeutral$65
May 7, 2026CitigroupMaintainedBuy$80 → $70
May 7, 2026Wells FargoMaintainedOverweight$76 → $62
May 7, 2026Evercore ISI GroupMaintainedIn-Line$54 → $50

Peers & ETF holders

TECH peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

34/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Wall Street analysts released a negative consensus forecast for Bio-Techne (TECH), labeling it as one of two stocks to sell. The consensus price target was set at $70.50, implying a 2.7% return that is below expectations. The recommendation reflects concerns over the company’s valuation and potential earnings pressure. The analysis highlighted that the sell call is part of a broader downbeat outlook for the sector.
What did this article say?
Bio‑Techne Corporation (NASDAQ: TECH) opened a new Good Manufacturing Practice facility in Bristol, United Kingdom, on October 8, 2026. The plant adds small‑molecule GMP production capacity, complementing existing sites in St. Paul and Minneapolis. The expansion strengthens TECH’s ability to support the rapidly growing cell therapy market from discovery through commercial manufacturing. The move signals a strategic investment in scalable production infrastructure, positioning TECH to meet increasing demand from therapy developers.
What did this article say?
On September 30, a Form 4 filing disclosed that John L. Higgins, a director of Bio‑Techne (NASDAQ:TECH), exercised a sizable block of company stock options worth approximately $751,000. The transaction indicated that a senior insider believed the company’s valuation was undervalued at the time of exercise. The move was reported as a positive signal of confidence in TECH’s future prospects. No immediate impact on guidance or earnings was noted. The filing was the sole material event reported for the period.
What did this article say?
The article compares Techne (TECH) and Incyte (INCY) for value investors, noting Techne’s Zacks Rank of #3 (Hold) versus Incyte’s #2 (Buy). It highlights that Techne’s earnings outlook is less improved than Incyte’s, based on recent estimate revisions. The piece explains how the Style Scores’ Value grade incorporates fundamental metrics to assess undervaluation. No material corporate action or earnings release is discussed, so the analysis is purely comparative. The overall tone is neutral, presenting both companies side‑by‑side without a clear recommendation.
What did this article say?
On September 23, Bio‑Techne shareholders approved Merck KGaA’s $73‑per‑share cash acquisition, valuing the company at roughly $11.3 billion including debt. The deal was accompanied by a rejection of the proposed executive compensation package, an uncommon move in such transactions. The acquisition aligns Merck’s existing life‑sciences portfolio with Bio‑Techne’s consumable reagents, proteins, and antibodies, creating a stronger foothold in laboratory supply chains. Regulatory clearance is expected within months, positioning the transaction for a swift close. The approval signals confidence in the strategic fit and financial terms, despite the share price closing slightly below the offer level.
What did this article say?
On September 24, Robert V Baumgartner, a board member of Bio‑Techne (NASDAQ:TECH), exercised a substantial block of company stock options, realizing approximately $754,000 in gains. The transaction was disclosed in a new SEC filing and reflects a routine insider activity. The exercise does not indicate any change in the company’s strategic direction or financial outlook. It is a standard corporate governance event with no immediate impact on the stock’s valuation or operational performance.
What did this article say?
Bio‑Techne shareholders approved a $73‑per‑share acquisition by Merck KGaA, clearing the Hart‑Scott‑Rodino waiting period and setting a closing window for late 2026 or early 2027. The deal values TECH at $11.3 billion and signals a strategic shift toward a larger European biopharma platform. The announcement is expected to lift investor confidence and may prompt a short‑term rally as the market prices in the premium and integration synergies.
What did this article say?
Analysts highlight that Bio‑Techne’s organic revenue growth has lagged the sector, averaging only 2.8% year‑on‑year over the past two years. Despite recent solid quarterly results, the company’s core research‑tool business shows signs of waning demand. The report cautions that the stock’s recent 39.5% gain may not be sustainable and recommends caution for investors considering exposure.

Technical Analysis

Real-time indicators across multiple timeframes

67
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.39B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell17,810,87811.35%$1.05B2026-01-29
BlackRock, Inc.▲ Buy14,025,8168.94%$990.92M2026-08-07
FMR LLC (Fidelity)▲ Buy12,794,7848.15%$903.95M2026-08-13
Goldman Sachs Group Inc▲ Buy7,343,3244.68%$518.81M2026-08-14
Morgan Stanley▼ Sell6,374,7174.06%$450.37M2026-08-13
Geode Capital Management, LLC▲ Buy5,351,4643.41%$377.54M2026-08-12
Invesco Ltd.▲ Buy4,986,4243.18%$352.29M2026-08-14
Ruane, Cunniff & Goldfarb L.P.▼ Sell3,348,8412.13%$236.60M2026-08-14
Neuberger Berman Group LLC▼ Sell2,844,6921.81%$200.98M2026-08-13
Capital Research Global Investors▼ Sell2,621,8901.67%$185.24M2026-08-12
Whitebox Advisors LLC▲ New2,100,0011.34%$148.37M2026-08-14
JPMorgan Chase & Co▲ Buy1,862,8051.19%$132.60M2026-08-12
Maverick Capital Ltd▼ Sell1,535,6100.98%$108.49M2026-08-14
AllianceBernstein L.P.▼ Sell2,002,0261.28%$104.63M2026-08-14
Norges Bank▼ Sell1,413,6390.90%$99.87M2026-08-12
Northern Trust Corp▼ Sell1,311,1880.84%$92.64M2026-08-13
Millennium Management LLC▲ Buy989,0330.63%$69.88M2026-08-14
Citadel Advisors LLC▲ Buy965,9180.62%$68.24M2026-09-02
Bank of America Corp▼ Sell955,2370.61%$67.49M2026-08-14
Balyasny Asset Management L.P.▲ Buy836,8700.53%$59.12M2026-08-14
Capital World Investors▲ Buy536,9620.34%$37.94M2026-08-12
Soros Fund Management LLC▲ New535,4000.34%$37.83M2026-08-14
Pentwater Capital Management LP▲ New500,0000.32%$35.33M2026-08-14
Citigroup Inc▲ Buy445,1450.28%$31.45M2026-08-03
Verition Fund Management LLC▲ Buy438,7460.28%$31.00M2026-08-14
Q2 2026 flow:19.43M sh bought ($1.37B)7.13M sh sold ($499.75M)net +12.31M sh (+$873.73M)
Congressional Trading Activity
11 disclosed trades · ~$88.0K est. traded value · 3 buys, 8 sells
MemberChamberStateTypeAmountTradedFiled
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-04-082026-05-06
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-03-262026-04-06
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-02-242026-03-10
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-01-282026-02-02
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-12-022026-01-05
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-10-222025-11-04
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-08-012025-09-02
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2025-05-262025-07-02
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-04-092025-05-02
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Thom TillisSenateNC▼ Sell$1K - $15K2015-02-132015-02-26